Needham Reiterates Buy on Praxis Precision Medicine, Maintains $250 Price Target

Benzinga · 12/01/2025 10:37
Needham analyst Ami Fadia reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $250 price target.